Ongoing investigations in the US have revealed telemedicine’s vulnerability to fraudulent activity, with the recent Operation ‘Happy Clickers’ targeting fraud losses of more than $7m. We find out how fraudsters are gaming the US healthcare system under the guise of telemedicine and what can be done about it.
Last year, a court told the FDA it had wrongly classified a device as a drug, raising questions about how medicines and devices are defined by the agency. In this issue, we explore which products fall into the grey area between drugs and devices and the financial and regulatory consequences for companies whose products are moved from one category to another.
Also in this issue, we speak to XIL Health founder and CEO Susan Lang about the future potential of 3D printed drugs. We hear why Lang believes 3D printing in drug manufacturing could revolutionise personalised medicine, democratise access to medicines, improve sustainability in the supply chain and speed up the response time when infectious diseases spread.
You can also subscribe here to receive email notifications when a new issue is available.